Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Granaticin B,Venetoclax,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lin BioScience Receives U.S. FDA Fast Track Designation for LBS-007
Details : LBS-007 is a natural, non-ATP cell cycle inhibitor targeting a broad array of cancers. It is being evaluated for the treatment of patients with relapsed or resistant acute leukaemias.
Brand Name : LBS-007
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 27, 2024
Lead Product(s) : Granaticin B,Venetoclax,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?